Pfizer drug from Medivation deal shows promise in breast cancer: study

(Reuters) - A breast cancer drug that Pfizer Inc acquired with its $14 billion purchase of Medivation showed promising anti-tumor activity following prior treatments and a modest ability to hold the disease in check, according to data from a mid-stage study released on Wednesday.